Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Lowered by Focus Financial Network Inc.

Focus Financial Network Inc. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 476 shares of the biopharmaceutical company’s stock after selling 62 shares during the quarter. Focus Financial Network Inc.’s holdings in Regeneron Pharmaceuticals were worth $339,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Creative Planning boosted its position in shares of Regeneron Pharmaceuticals by 22.7% during the third quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock worth $12,397,000 after buying an additional 2,178 shares during the period. Bfsg LLC lifted its position in Regeneron Pharmaceuticals by 3,352.0% in the third quarter. Bfsg LLC now owns 863 shares of the biopharmaceutical company’s stock worth $907,000 after purchasing an additional 838 shares during the period. Tamar Securities LLC lifted its position in Regeneron Pharmaceuticals by 16.6% in the third quarter. Tamar Securities LLC now owns 15,492 shares of the biopharmaceutical company’s stock worth $16,286,000 after purchasing an additional 2,211 shares during the period. Greater Midwest Financial Group LLC lifted its position in Regeneron Pharmaceuticals by 0.7% in the third quarter. Greater Midwest Financial Group LLC now owns 2,520 shares of the biopharmaceutical company’s stock worth $2,649,000 after purchasing an additional 18 shares during the period. Finally, Good Life Advisors LLC lifted its position in Regeneron Pharmaceuticals by 60.0% in the third quarter. Good Life Advisors LLC now owns 384 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 144 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $674.27 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The stock has a fifty day moving average price of $710.88 and a two-hundred day moving average price of $901.80. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The firm has a market capitalization of $74.10 billion, a P/E ratio of 17.61, a P/E/G ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.86 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on REGN shares. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Barclays reduced their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.